As officials clamp down on hundreds of products, including a brand backed by David Beckham, the future could be changing for cannabidiol In the past 10 years cannabidiol or CBD has become a staple in what seems like every…
Is CBD a miracle cure or snake oil?
They call it the “green rush”. When 23-year-old Jonny Alberto co-founded his CBD company, The Good Level, last year, he joined a flow of fortune seekers who had built a £690 million market – the biggest in Europe, and worth more than that of Vitamin C and D supplements combined. But as with the original gold rush, as deposits were depleted and workers disappointed, it is crunch time for CBD.
If you are unfamiliar with CBD (cannabidiol), you need only look on high street shelves, where it is sold in countless formats: oils, liquids for e-cigarettes, sprays, supplements, shampoos, skincare, gummy bears, chewing gum, tampons and even dog chews. Holland and Barrett alone stocks more than 200 CBD lines, from £1.99 for a can of CBD-infused juice to £99.99 for 30ml of premium CBD oil.
CBD is one of more than 100 compounds found in the hemp plant. Unlike THC – Tetrahydro-cannabinol – it is legal in the UK, and doesn’t have psychoactive effects, so it won’t get you “high”.
Puffed up by endorsements from celebrities including Anthony Joshua, Claudia Winkleman and David Beckham (who bought a five per cent stake in the company Cellular Goods), CBD rapidly rose in popularity following the legalisation of medicinal cannabis in 2018.
Customers come to Alberto’s shop in west London to buy CBD oils and balms they hope will solve sleeplessness, anxiety or chronic pain. But if they ask Alberto what CBD does, he’s not allowed to tell them. “It’s tough. We don’t recommend doses anymore, and making medical claims is not something we’re allowed to do.”
CBD is what the Government labels a “novel food”, meaning it has no history of consumption before 1997 (even if some experts argue otherwise). It’s not a medicine, owing to a paucity of clinical evidence, and it cannot be marketed with health claims – but Alberto says some sellers get around this by saying “it may help, or has a possibility to help” with certain conditions.
Now The Food Standards Agency (FSA) has begun to regulate the market and has published a list of sanctioned CBD products that “have a credible application for authorisation”. They have been assessed based on scientific information including compositional data and a toxicology report. More than 900 applications were submitted, but only “around 70” made the cut. Those that didn’t succeed lacked credible information or did not submit it in time. Products not on the list – including those from Beckham-backed Cellular Goods – must be removed from sale.
A report from Emily Miles, the FSA’s chief executive, to the board in December 2021 identified the potential for “adverse side effects” from CBD based on a report from the Committee on Toxicity and said “the quality of applications was lower than we anticipated… While we haven’t yet been shown enough evidence to say that CBD is unsafe, nor is there enough evidence to show that it is safe.”
Professor David Nutt is the UK’s foremost expert on neuropsychopharmacology and the author of a new book, Cannabis (Seeing Through the Smoke): The New Science of Cannabis and Your Health. “If you put it to a survey, you’d probably find 50 per cent of people using CBD say it improves their sleep. In my mind, that’s pretty good evidence. But it’s not a clinical trial.” In any case, he insists CBD is “ridiculously safe”.
The lack of clinical trials shouldn’t matter, he argues, as CBD is sold as a health supplement rather than a medicine. “We don’t demand most of the things you buy in food shops to have a pharmaceutical analysis of purity.”
The new legislation has caused problems for entrepreneurs. Tony Calamita, CEO of Love Hemp, has spoken of his struggles to open a bank account in a climate of mistrust for CBD brands. A market that was experiencing double-digit growth has nosedived; share prices for Cellular Goods have tumbled by more than 80 per cent in the past six months.
Yet despite the fact that sellers can’t brag about CBD’s benefits, there is no shortage of anecdotal evidence or users willing to evangelise on its behalf. It is pitched as a panacea for all manner of modern ills, and said to alleviate anxiety, insomnia, inflammation and low mood. Users fervently swear that it treats conditions as varied as arthritis, PTSD and Crohn’s disease.
Over-the-counter CBD is different to medical cannabis, which includes the high-strength CBD legalised for the treatment of certain rare types of childhood epilepsy in 2018.
This is where it gets technical. “What you’re buying over the counter is pure cannabidiol extract,” says Nutt. “There is a difference between cannabidiol which is extracted from the cannabis plant, and cannabidiol which is part of the hemp plant, where you get all the other elements to get what we call the ‘entourage effect’. The former is legal, the latter is controversial. My belief is that the whole plant is better than the pure extract.”
Alberto is one of a handful of sellers making “full spectrum” CBD oil, which contains the other compounds Nutt refers to, but still no more than the legal limit of 0.2 per cent THC. His company is excluded from the FSA’s clampdown on a technicality, as cold-pressed CBD oil is not subject to the same laws as oil extracted by different methods. For businesses and consumers, the rules are hazy.
“CBD sellers are in a double bind… it’s a lose-lose situation for them,” says Nutt. “[The FSA] is looking for reasons not to allow it rather than ways to facilitate it… because it’s got the word ‘can’ in it, ‘can’ is cannabis, and cannabis is dangerous.”
As with any industry, Alberto says there are goodies and baddies. There are cowboys “just trying to make a quick buck”, he says, “and those are the people that the FSA needs to kick out. The good guys in the industry really want the legislation to come in… There are big players on the market who have illegal amounts of THC. The FSA are starting to shut people down – there are a few that have been shut already.”
Research conducted by the Centre for Medicinal Cannabis in 2019 found almost two-thirds of the over-the-counter CBD products analysed contained less than 90 per cent of the CBD advertised on the label, some contained more, and 45 per cent contained illegal levels of THC.
If you look closely, is the over-the-counter CBD market little more than a puff of hot air? Even Nutt admits there is a placebo effect at play. “If you’ve got a little bit of anxiety, maybe 30 milligrams of CBD might have a similar effect as having a drink. It probably isn’t going to work, but who knows? It gives you some moral courage.”
Other experts say no, over-the-counter CBD almost definitely won’t work. “I think it just caught on in the public imagination, despite the fact that we’ve only ever seen therapeutic benefit with very high doses, and they’re still very early trials,” says Lucy Chester of King’s College London’s department for psychosis studies. “If someone finds something they think is working for them, then it works – but there’s just not the evidence behind it.”
Dr Mikael Sodergren, head of Imperial College London’s Medical Cannabis Research Group, has been treating patients with CBD and medical cannabis at his Harley Street practice since it was legalised. The medical CBD prescribed in his clinic, he says, bears no resemblance to “wellness products”, which are of unknown quality.
“The CBD we prescribe as medicine has to undergo GMP [Good Manufacturing Practice] processing and tick all the boxes for the Medicines and Healthcare products Regulatory Agency. Neither of those things are applicable to high street CBD, which is essentially unregulated,” he says. “The third point is that the doses we use medicinally are an order of magnitude higher.” Participants in a study for the efficacy of CBD might be given 600mg in one dose, whereas the FSA (and so CBD brands) suggest no more than 70mg over the course of a day.
Extracting CBD from the hemp plant is an art as well as science, and some variation is natural. “CBD is what we call a ‘dirty drug’ – it affects lots of different receptors, but not the ones you’d think,” Chester says. “One of the reasons CBD research is quite confusing is we’re still not entirely sure how it works.”
If it’s a con, it’s a convincing one. As well as those who say CBD improves their sleep and reduces anxiety, people say it can cause physical healing of biblical proportions. “There was one guy who came in the other day who had had a stroke seven years ago and hadn’t been able to walk properly since,” says Alberto. “And four or five days later he returned and said, ‘I can’t believe it.’ So for those people, it really changes their life.”
Depending on who you ask, CBD is snake oil, a medical miracle, a rip-off or a wonder drug. The watchdog is wary, but CBD has already captured the consumer’s imagination.
Alberto insists CBD will become so widely accepted that it’s as commonplace as echinacea or multivitamins. “In some states in America, people have it in the medicine cabinet, just in case someone’s got a headache or someone’s in pain,” he says. “That’s where it’s going to go in the UK.”
Only time – and, hopefully, research – will tell if his optimism will pay off.
Curious Cure-all or Silly Snake-oil?: What Scientists Think About CBD
In the past 10 years cannabidiol or CBD has become a staple in what seems like every.
June 8, 2021
In the past 10 years cannabidiol or CBD has become a staple in what seems like every industry imaginable. From CBD oil infused pillows to CBD toothpicks, you can’t walk 10 feet without finding some new, eclectic CBD product. You have likely heard of the innumerable positive effects of CBD, but which ones are true and which ones are utter nonsense? Today we are going to break down the scientifically proven effects of cannabidiol!
Before we discuss the medicinal properties of the chemical, I want to provide you with a bit of background on what exactly CBD is. Cannabidiol is a chemical compound found in cannabis. While it does not produce an altered state of mind like THC, the active ingredient in cannabis, it has been speculated to have many healing properties (Grinspoon, 2018). CBD is thought to bind to CB2 receptors throughout the nervous system. The CB2 receptor is heavily expressed in immune system cells and is thought to play a role in neuroinflammation (Maroon & Bost, 2018).
In recent years, there has been an explosion of research surrounding the therapeutic effects of CBD. The data suggests that CBD:
- Can reduce anxiety (Blessing et al., 2015; Guimaraes et al., 1990; Zuardi et al., 1982).
- Can assist in the regulation of heart rate, blood pressure, and is helpful in reducing damage post stroke and heart attack, IN ANIMALS (not enough data is out there about humans at this point) (Sultan et al., 2017).
- Can help reduce some symptoms of schizophrenia (Mcguire et al., 2018).
- Can provide pain relief (Johnson et al., 2010).
- Can help with insomnia (Crippa, 2003).
- Can reduce seizures in treatment resistant epileptic disorders (Grinspoon, 2018).
While there are many studies touting the positive effects of CBD, more research should be conducted to further corroborate the existing data. The only FDA approved treatment involving the use of CBD is in the treatment of several childhood epileptic disorders. While CBD seems to have a low side-effect profile, due to the novelty of CBD research there is not a large swath of data on all of the potential drug interactions. Though CBD has a lot of potential for therapeutic use, it is important to keep this risk in-mind!